This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Eiger BioPharmaceuticals, Inc.
Drug Names(s): BMS-914143, IL-29, Interleukin-29, PEG-rIL-29, PEG-IFN lambda, Peginterferon lambda, Lambda
Description: IL-29 is a cytokine. The native human protein Interferon lambda is generated by the immunesystem in response to viral infection. It mediates anti-viral activity through a receptor that is distinct from that used by Interferon alpha and is generally present on fewer cell types within the tissues of the body.
Cytokines play a critical role in modulating the innate and adaptive immune systems. PEG-Interferon lambda signals through a receptor with a more restricted expression pattern than that used by type-I interferons alpha, beta and omega.
Bristol-Myers Squibb and ZymoGenetics
In January 2009, Bristol-Myers Squibb and ZymoGenetics announced a global collaboration for PEG-Interferon lambda.
Under the terms of the collaboration, Bristol-Myers Squibb agreed to pay ZymoGenetics an upfront cash payment of $85 million for the development and commercialization rights to PEG-Interferon lambda, and to pay an additional license fee of $20 million in 2009. ZymoGenetics could receive additional payments of up to $430 million based on pre-defined development and regulatory milestones for PEG-Interferon lambda in Hepatitis C, up to $287 million in development and regulatory milestones for other potential indications, and up to $285 million based on pre-defined sales-based milestones.
The companies have agreed to co-develop PEG-Interferon lambda in the United States and Europe and will share development costs. It is anticipated that ZymoGenetics will conduct a significant portion of continuing Phase I and certain...See full deal structure in Biomedtracker
Partners: Bristol-Myers Squibb Company
PEG-Interferon lambda News
Additional information available to subscribers only: